Ge Longhui 21st November丨Bio-Thera Solutions (688177.SH) stated on the interactive platform that the company's Bevacizumab monoclonal antibody has not yet started sales in the European Union and USA; TOFIDENCE (Tuzumab monoclonal antibody) started sales in the USA in May this year, and the listing time in the European Union is yet to be determined. Other overseas markets have not yet been approved for listing, and the company will actively follow up to promote the relevant processes. The company recognizes revenue in accordance with accounting standards, and part of the 10 million milestone from Hikma is included in the revenue. For specific information on the breakdown of revenue, please refer to the company's disclosure in the "Bio-Thera Solutions 2024 Interim Report" in statutory media.
- Headlines
- Bio-thera solutions (688177.SH): The company’s bevacizumab has not yet started selling in the EU and the usa.
百奥泰(688177.SH)：公司贝伐珠单抗在欧盟和美国尚未开始销售
Bio-thera solutions (688177.SH): The company’s bevacizumab has not yet started selling in the EU and the usa.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Latest
11:48
Japan's top Forex official Jun Mimura: As non-G7 countries gradually reduce their dependence on G7 currencies, it is necessary to consider how to maintain the competitiveness of the yen through the G7 framework.
11:46
Japan's top Forex official, Jun Mimura, emphasized the necessity of maintaining trust in the yen by addressing fiscal health issues.
11:43
Nomura: Maintains CHINA MOBILE (00941) "Buy" rating, Target Price lowered to 88 Hong Kong dollars.
CHINA MOBILE-0.07%
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.